GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AREV Life Sciences Global Corp (OTCPK:AREVF) » Definitions » Equity-to-Asset

AREV Life Sciences Global (AREV Life Sciences Global) Equity-to-Asset : -5.48 (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is AREV Life Sciences Global Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. AREV Life Sciences Global's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $-0.86 Mil. AREV Life Sciences Global's Total Assets for the quarter that ended in Sep. 2023 was $0.16 Mil.

The historical rank and industry rank for AREV Life Sciences Global's Equity-to-Asset or its related term are showing as below:

AREVF' s Equity-to-Asset Range Over the Past 10 Years
Min: -92   Med: -0.43   Max: 0.9
Current: -5.46

During the past 13 years, the highest Equity to Asset Ratio of AREV Life Sciences Global was 0.90. The lowest was -92.00. And the median was -0.43.

AREVF's Equity-to-Asset is ranked worse than
96.96% of 1087 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs AREVF: -5.46

AREV Life Sciences Global Equity-to-Asset Historical Data

The historical data trend for AREV Life Sciences Global's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AREV Life Sciences Global Equity-to-Asset Chart

AREV Life Sciences Global Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.60 -0.50 -0.15 -3.77

AREV Life Sciences Global Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.34 -3.77 -3.68 -4.88 -5.48

Competitive Comparison of AREV Life Sciences Global's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, AREV Life Sciences Global's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AREV Life Sciences Global's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AREV Life Sciences Global's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where AREV Life Sciences Global's Equity-to-Asset falls into.



AREV Life Sciences Global Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

AREV Life Sciences Global's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=-0.702/0.186
=-3.77

AREV Life Sciences Global's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=-0.86/0.157
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AREV Life Sciences Global  (OTCPK:AREVF) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


AREV Life Sciences Global Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of AREV Life Sciences Global's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


AREV Life Sciences Global (AREV Life Sciences Global) Business Description

Traded in Other Exchanges
N/A
Address
91 Golden Drive, Unit 18, Coquitlam, BC, CAN, V3K 6R2
AREV Life Sciences Global Corp is a fully integrated, early stage life science discovery enterprise dedicated to delivering solutions to public healthcare metrics through innovations and successful collaborations in the life science industry. The Company's focuses on dedication to generate revenue by way of novel therapeutic approaches to human nutrition and malnutrition, pandemic diseases, and neglected chronic co-morbidities.

AREV Life Sciences Global (AREV Life Sciences Global) Headlines